0GP7.LMedivir AB (publ)

À propos

Established in 1987 and headquartered in Huddinge, Sweden, Medivir AB (publ) is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products. Its primary therapeutic area is oncology, with operations extending across Sweden and internationally. The company's marketed product, Zoviduo (also known as Xerclear), treats labial herpes. Medivir's robust pipeline features several investigational compounds: Remetinostat for MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818 for liver cancer; MIV-711 for osteoarthritis; and Birinapant along with IGM-8444, both targeting solid tumors. Furthermore, Medivir engages in strategic collaborations, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS-CoV-2, and has licensing agreements with Tango Therapeutics and Ubiquigent Limited for preclinical research programs, specifically Ubiquigent's USP7 program.

www.medivir.com

Statistiques clés

Capitalisation

204.94M

BPA

-0.66

Rendement dividende

0.00%

Bêta

0.11

P/B

0.25

ROE

-35.7%

Secteur

Healthcare

Industrie

Medical - Pharmaceuticals

PDG

Jens Lindberg

Employés

10

Date IPO

2023-06-07

Pays

SE